ENTX Stock Summary and Trading Ideas (Entera Bio Ltd. - | NASDAQ:ENTX)

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Entera Bio Ltd. - trades on the NASDAQ stock market under the symbol ENTX.

As of October 2, 2026, ENTX stock price declined to $2.86 with 97,249 million shares trading.

ENTX has a beta of -0.91, meaning it tends to be less sensitive to market movements. ENTX has a correlation of 0.01 to the broad based SPY ETF.

ENTX has a market cap of $495.19 million. This is considered a Small Cap stock.

In the last 3 years, ENTX traded as high as $4.20 and as low as $.52.

ENTX has outperformed the market in the last year with a return of +52.1%, while the SPY ETF gained +16.1%. In the last 3 month period, ENTX beat the market returning +72.3%, while SPY returned +3.6%. However, in the most recent 2 weeks ENTX has underperformed the stock market by returning -3.4%, while SPY returned +1.0%.

ENTX support price is $2.75 and resistance is $3.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENTX shares will trade within this expected range on the day.